At ReForm, we are not only developing our own pipeline of biobetter biologics formulations, we are working with biopharmaceutical partners to advance and improve the characteristics of their biologics.
Formulating highly concentrated biopharmaceuticals present challenges due to viscosity. Most biologics are dosed intravenously and require multiple dosing regimens because these viscous materials need to be diluted and administered via prolonged infusions. In many cases, subcutaneous injection would be preferred, but viscosity interferes with injecting large doses through fine-gauge needles.
ReForm Biologics works with our partners to address these challenges. ReForm offers a portfolio of science-based platforms to assist our partners in meeting their product development goals and their patients’ needs for more easily administered and better tolerated biologic therapeutics.
We extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for our biopharmaceutical partners. We offer formulation development collaboration and product-specific licenses for a broad spectrum of protein-based therapeutics.
ReForm structures its partnerships in an open and science-driven manner, to collaborate with pharmaceutical companies as they develop innovative biologic treatments.
Jeff Hackman, CEO, Reform
12 Gill Street, Suite 4650
Woburn, MA 01801, USA